To The Moon

$Hims & Hers Health Inc.(HIMS)$ 🚨⚖️💊HIMS vs Big Pharma: Crackdown or Correction?💊⚖️🚨

$HIMS just got smacked with a seismic downgrade. Needham has pulled it off their Conviction List and downgraded the stock to Hold, following the abrupt termination of its high-profile GLP-1 distribution deal with Novo Nordisk. The stock cratered over 30% intraday to $44.08, breaking through key Fibonacci resistance and testing the 1.272 extension.

But is this the end of the bull thesis or a rare asymmetric setup in disguise?

This post unpacks everything, the analyst downgrade, insider sourcing claims, technical positioning, and forward setups.

📉 Catalyst: Novo Pulls the Plug

Needham’s note cited “deceptive promotion” and “illegitimate Wegovy knockoffs” as reasons behind Novo Nordisk’s decision to walk away. That’s a damning accusation, and it wasn’t subtle. Novo stated it would no longer distribute Wegovy through HIMS’ platform, cutting off access via NovoCare Pharmacy.

Shares in $HIMS dropped nearly 33%, while Novo $NVO also dipped 5.6% in premarket on 24Jun25, 🇳🇿NZ Time.

🧬 Legal Shock or Competitive Smokescreen?

Novo’s press release was direct. The Danish pharma titan is halting HIMS’ access to Wegovy via NovoCare, citing concerns over unregulated GLP-1 sales. But just hours later, a former HIMS VP of Pharmacy revealed that HIMS and Novo source GLP-1 active ingredients from the same supplier in China. This raises serious questions about the legitimacy of Novo’s claim.

If both parties use the same manufacturer, the issue might be less about health safety and more about competitive channel control, especially as telehealth upstarts threaten legacy pharma’s grip on direct-to-consumer models.

The true risk now isn’t just regulatory, it’s narrative control. And Novo just flipped that chessboard.

📉 Needham Downgrade: Key Takeaways

Needham’s analyst flagged three major headwinds:

   •   Regulatory exposure due to HIMS’ use of the 503A compounding loophole

   •   Loss of strategic backing now that both Novo and Eli Lilly support HIMS competitors

   •   Legal uncertainty that could weigh on the stock for months, keeping it range bound

Analyst sentiment has shifted to cautious, with no clear resolution in sight.

📊 Technical View: Breakdown but Not Breakout Failure

HIMS dropped below the 1.272 Fibonacci extension at $46.64, hitting a low of $43.13 before bouncing slightly. The daily and monthly charts offer two key zones to monitor:

   •   Short-Term Support: The Ichimoku Tenkan-sen at $44.52 is still holding. As long as it holds into month end, the broader bull trend remains intact.

   •   Volume Shelf Buy Zone: Strong historical volume between $35–$39 signals this as a high probability re-entry area. If panic persists, expect that zone to attract institutional bids.

   •   MACD + RSI: Momentum is slowing, but not reversed. RSI(6) at 42.41 shows mild downside risk, while MACD remains positive but has lost pace.

This isn’t a complete technical breakdown yet. But bulls must reclaim $46.64 fast to avoid further derating.

🧭 Scenario Outlook: Bullish Setup or Bear Trap?

Let’s run the most likely scenarios heading into July:

Scenario 1: Legal Overhang Grows (45%)

If regulators act on Novo’s claims, or if perception of non-compliance sticks, expect HIMS to remain capped below $50 for the foreseeable future. Traders may avoid size until legal clouds clear.

Scenario 2: Narrative Flips (35%)

If HIMS clarifies sourcing and demonstrates alignment with regulatory standards, especially if it provides third-party audit or FDA verification, a sentiment reversal could drive recovery toward the $55–$60 zone.

Scenario 3: Accumulation Rebuilds (20%)

If the price drops to the $35–$39 buy zone, institutions may quietly accumulate ahead of clarity. A sharp bounce could follow, especially if insider buying is reported or volume spikes return.

🎯 Strategy Consideration

Rather than chasing weakness or bottom ticking, strategic traders might look to sell $35 cash secured puts, generating premium while positioning to own the stock near its volume weighted sweet spot.

Alternatively, high risk reward setups might come from watching for a reclaim of the 20-day MA at $44.27 on strong volume, a signal that dip buyers are reloading.

🧨 Macro Context: Pharma’s Platform Wars

This isn’t just about HIMS. It’s about how telehealth disruptors are colliding with entrenched pharma giants. Novo’s decision may have as much to do with defending pricing power and retail shelf space as it does with clinical integrity. If HIMS weathers this, it reinforces the viability of lean, digitally native healthcare platforms operating outside traditional gatekeeping models.

In that light, this week’s drawdown could be a long-term gift for those with conviction, not a death knell.

🔍 Key Watchlist for Confirmation

   •   Monthly close above $44.52 Tenkan

   •   Any SEC or FDA statement clarifying HIMS’ regulatory standing

   •   Insider buys or increased institutional inflow around $35–$39

   •   Open interest build up on $50+ calls into July

💥 Final Take

This is what high conviction risk looks like. Uncertainty. Volatility. Panic. But if the sourcing claim is accurate, that HIMS and Novo are aligned, then this isn’t a thesis breaker. It’s a mispriced dislocation. There’s still a credible long-term case here, but it now hinges on narrative control and legal visibility.

I’m not diving in blindly. But I’m watching every candle, every filing, every option contract. If this rebounds, it won’t be because the crowd saw it coming, it’ll be because the fog cleared, and only the brave were left standing.

📢 Don’t miss out! Like, Repost and Follow me for exclusive setups, cutting-edge trends, and insights that move markets 🚀📈 I’m obsessed with hunting down the next big movers and sharing strategies that crush it. Let’s outsmart the market and stack those gains together! 🍀

Trade like a boss! Happy trading ahead, Cheers, BC 📈🚀🍀🍀🍀

@Tiger_comments @TigerObserver @TigerWire @TigerPicks @TigerStars @Daily_Discussion @TigerClub